131 related articles for article (PubMed ID: 18613768)
1. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.
Camidge DR
Expert Opin Biol Ther; 2008 Aug; 8(8):1167-76. PubMed ID: 18613768
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.
Adams C; Totpal K; Lawrence D; Marsters S; Pitti R; Yee S; Ross S; Deforge L; Koeppen H; Sagolla M; Compaan D; Lowman H; Hymowitz S; Ashkenazi A
Cell Death Differ; 2008 Apr; 15(4):751-61. PubMed ID: 18219321
[TBL] [Abstract][Full Text] [Related]
3. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Ross J; Fong S; Carano R; Totpal K; Lawrence D; Zheng Z; Koeppen H; Stern H; Schwall R; Ashkenazi A
Clin Cancer Res; 2008 Dec; 14(23):7733-40. PubMed ID: 19047100
[TBL] [Abstract][Full Text] [Related]
4. Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer.
Zinonos I; Labrinidis A; Lee M; Liapis V; Hay S; Ponomarev V; Diamond P; Zannettino AC; Findlay DM; Evdokiou A
Mol Cancer Ther; 2009 Oct; 8(10):2969-80. PubMed ID: 19808976
[TBL] [Abstract][Full Text] [Related]
5. TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam D; Szegezdi E; Keane M; de Jong S; Samali A
Cancer Treat Rev; 2009 May; 35(3):280-8. PubMed ID: 19117685
[TBL] [Abstract][Full Text] [Related]
6. Development of a radioiodinated apoptosis-inducing ligand, rhTRAIL, and a radiolabelled agonist TRAIL receptor antibody for clinical imaging studies.
Duiker EW; Dijkers EC; Lambers Heerspink H; de Jong S; van der Zee AG; Jager PL; Kosterink JG; de Vries EG; Lub-de Hooge MN
Br J Pharmacol; 2012 Apr; 165(7):2203-12. PubMed ID: 22014269
[TBL] [Abstract][Full Text] [Related]
7. Targeting the extrinsic apoptosis pathway in cancer.
Ashkenazi A
Cytokine Growth Factor Rev; 2008; 19(3-4):325-31. PubMed ID: 18495520
[TBL] [Abstract][Full Text] [Related]
8. [Leukemic cell apoptosis induced by anti-human DR5 monoclonal antibody mDRA-6].
Li SL; Ma YF; Liu GC; Zhang J; Bai HL; Liu YJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Aug; 23(8):754-6. PubMed ID: 17618571
[TBL] [Abstract][Full Text] [Related]
9. Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.
Bajaj M; Heath EI
Expert Opin Biol Ther; 2011 Nov; 11(11):1519-24. PubMed ID: 21877997
[TBL] [Abstract][Full Text] [Related]
10. Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity.
Finnberg NK; Gokare P; Navaraj A; Lang Kuhs KA; Cerniglia G; Yagita H; Takeda K; Motoyama N; El-Deiry WS
Cancer Res; 2016 Feb; 76(3):700-12. PubMed ID: 26609054
[TBL] [Abstract][Full Text] [Related]
11. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.
Camidge DR; Herbst RS; Gordon MS; Eckhardt SG; Kurzrock R; Durbin B; Ing J; Tohnya TM; Sager J; Ashkenazi A; Bray G; Mendelson D
Clin Cancer Res; 2010 Feb; 16(4):1256-63. PubMed ID: 20145186
[TBL] [Abstract][Full Text] [Related]
12. Targeting TRAIL death receptors.
Oldenhuis CN; Stegehuis JH; Walenkamp AM; de Jong S; de Vries EG
Curr Opin Pharmacol; 2008 Aug; 8(4):433-9. PubMed ID: 18625341
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
[TBL] [Abstract][Full Text] [Related]
14. TRAIL death receptors and cancer therapeutics.
Huang Y; Sheikh MS
Toxicol Appl Pharmacol; 2007 Nov; 224(3):284-9. PubMed ID: 17240413
[TBL] [Abstract][Full Text] [Related]
15. TRAIL-receptor antibodies as a potential cancer treatment.
Buchsbaum DJ; Forero-Torres A; LoBuglio AF
Future Oncol; 2007 Aug; 3(4):405-9. PubMed ID: 17661715
[TBL] [Abstract][Full Text] [Related]
16. Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.
Rosevear HM; Lightfoot AJ; Griffith TS
Curr Opin Investig Drugs; 2010 Jun; 11(6):688-98. PubMed ID: 20496264
[TBL] [Abstract][Full Text] [Related]
17. Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels.
Beyrath J; Chekkat N; Smulski CR; Lombardo CM; Lechner MC; Seguin C; Decossas M; Spanedda MV; Frisch B; Guichard G; Fournel S
Oncotarget; 2016 Oct; 7(40):64942-64956. PubMed ID: 27409341
[TBL] [Abstract][Full Text] [Related]
18. Death receptor agonist therapies for cancer, which is the right TRAIL?
Holland PM
Cytokine Growth Factor Rev; 2014 Apr; 25(2):185-93. PubMed ID: 24418173
[TBL] [Abstract][Full Text] [Related]
19. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.
Martin BP; Frew AJ; Bots M; Fox S; Long F; Takeda K; Yagita H; Atadja P; Smyth MJ; Johnstone RW
Int J Cancer; 2011 Jun; 128(11):2735-47. PubMed ID: 20715169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
